Navigation Links
Clinical Study Shows Sustamine(TM) L-Alanyl-L-Glutamine Increases Performance in Endurance, Exercise and Activity
Date:2/11/2010

NEW YORK, Feb. 11 /PRNewswire/ -- A clinical study by Dr. Jay Hoffman, PhD, professor and chair of the Department of Health and Exercise Science at the College of New Jersey, has shown Sustamine™ L-Alanyl-L-Glutamine, increases performance in endurance exercise and activity. The study was published on February 3, 2010, in the Journal of the International Society of Sports Nutrition (JISSN), a peer-reviewed journal covering various aspects of sports nutrition, supplementation, exercise metabolism, and/or scientific policies related to sports nutrition.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100211/SF53296LOGO)

The data published in the Journal of ISSN shows:

  • Significant performance reduction occurred when exercising to exhaustion in subjects' hypohydrated to 2.5% of body mass. 
  • When subjects ingested the Sustamine™ supplement during the rehydration period the magnitude of performance reduction was significantly less compared to the dehydrated condition. 
  • Water alone did not appear to significantly off-set the performance reduction.

The study showed the efficacy of Sustamine L-Alanyl-L-Glutamine ingestion during Hydration Stress under intense exercise. The clinical study covered the ability of Sustamine L-Alanyl-L-Glutamine to enhance fluid regulation in healthy, active individuals in relation to both endurance and high intensity exercise. Further discussion focuses on the potential ergogenic benefit that Sustamine™ has under these exercise and hydration stresses.  The role that this dipeptide has on the inflammatory, immune and recovery responses to these stresses was also examined.

Sustamine™ is the only GRAS (Generally Recognized As Safe) form of L-Alanyl-L-Glutamine for a variety of food, beverage and healthcare applications. It appears to increase electrolyte and fluid uptake across the intestines by increasing ion transport through an enhanced signaling pathway within the intestinal mucosal cells. Its implications for exercise are enhancement of fluid regulation during prolonged exercise in the heat, maintaining or enhancing performance during a hydration/heat stress, and enhancing recovery from exercise by modulating immune, inflammatory and oxidative stress responses to physical activity. 

Sustamine™, manufactured by Kyowa Hakko Bio Co. Ltd., is considered a "high-tech" amino acid dipeptide that promotes muscle rehydration, recovery and can be used as a source for energy refueling. Produced by a novel and cost effective patented fermentation technology, Sustamine™ L-Alanyl-L-Glutamine is available in powder form and is water-soluble into a clear solution. It is also odorless and tasteless.

Additional Sustamine™ highlights include:

  1. Patent pending for improved endurance performance
  2. Only stable form of glutamine for solutions or ready to drink beverages
  3. Stable in beverages with broad pH ranges
  4. Stable in beverages for over one year at room temperature

Dr. Hoffman's November 2009 SupplySide West seminar, Efficacy of Sustamine™ L-Alanyl-L-Glutamine Ingestion During Hydration Stress Under Intense Exercise is available for viewing at http://www.kyowa-usa.com/multimedia/nutritionals/.

Kyowa Hakko Bio is an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Hydrafend™ Hyaluronic Acid, Lumistor® L-Hydroxyproline, Setria® Glutathione, Kyowa CoQ10™ as well as Sustamine™ L-Alanyl-L-Glutamine.

Kyowa offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.

Additional information on Sustamine™ L-Alanyl-L-Glutamine can be found online at www.Kyowa-USA.com or contact Kyowa at Info@Kyowa-USA.com or

212-319-5353.

SOURCE Kyowa Hakko

RELATED LINKS
http://www.kyowa-usa.com
http://www.Sustamine.com

'/>"/>

SOURCE Kyowa Hakko
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
Breaking Medicine News(10 mins):